Table 1.

Baseline demographic and clinical characteristics of 31 patients with R/R CNS B-ALL and 158 patients with R/R B-ALL without CNS involvement

CharacteristicPatients with CNS disease (n = 31)Patients without CNS disease (n = 158)
Median age at CAR T-cell infusion (range), y 46.5 (24-76) 46 (18-81) 
Sex, n (%)   
Male 18 (58.1) 89 (56.3) 
Female 13 (41.9) 69 (43.7) 
ALL subtype, n (%)   
Ph 11 (35.5) 86 (54.4) 
Ph+ 14 (45.2) 41 (25.9) 
Ph-like 5 (16.1) 29 (18.4) 
MPAL 1 (3.2) 2 (1.3) 
CNS disease status at initial diagnosis, n (%)   
CNS-1 24 (77.4) 100 (63.3) 
CNS-2 2 (6.5) 10 (6.3) 
CNS-3 1 (3.2) 9 (5.7) 
Not assessed/unknown 4 (12.9) 39 (24.7) 
Median lines of therapy before CAR T-cell therapy, n (range) 4 (2-12) 3 (2-9) 
Previous therapies, n (%)   
Allogeneic HSCT 18 (58.1) 60 (38.0) 
Blinatumomab 19 (61.3) 93 (58.9) 
Inotuzumab ozogamicin 12 (38.7) 78 (49.5) 
Medullary disease status before apheresis, n (%)   
CR MRD-neg 6 (19.3) 22 (13.9) 
CR MRD-pos or unknown 11 (35.5) 40 (25.3) 
Active disease 14 (45.2) 80 (50.6) 
Unknown disease status 0 (0) 16 (10.1) 
CNS disease status before apheresis, n (%)   
CNS-1 0 (0) 96 (60.8) 
CNS-2 15 (48.4) 0 (0) 
CNS-3 16 (51.6) 0 (0) 
Unknown status 0 (0) 62 (39.2) 
CharacteristicPatients with CNS disease (n = 31)Patients without CNS disease (n = 158)
Median age at CAR T-cell infusion (range), y 46.5 (24-76) 46 (18-81) 
Sex, n (%)   
Male 18 (58.1) 89 (56.3) 
Female 13 (41.9) 69 (43.7) 
ALL subtype, n (%)   
Ph 11 (35.5) 86 (54.4) 
Ph+ 14 (45.2) 41 (25.9) 
Ph-like 5 (16.1) 29 (18.4) 
MPAL 1 (3.2) 2 (1.3) 
CNS disease status at initial diagnosis, n (%)   
CNS-1 24 (77.4) 100 (63.3) 
CNS-2 2 (6.5) 10 (6.3) 
CNS-3 1 (3.2) 9 (5.7) 
Not assessed/unknown 4 (12.9) 39 (24.7) 
Median lines of therapy before CAR T-cell therapy, n (range) 4 (2-12) 3 (2-9) 
Previous therapies, n (%)   
Allogeneic HSCT 18 (58.1) 60 (38.0) 
Blinatumomab 19 (61.3) 93 (58.9) 
Inotuzumab ozogamicin 12 (38.7) 78 (49.5) 
Medullary disease status before apheresis, n (%)   
CR MRD-neg 6 (19.3) 22 (13.9) 
CR MRD-pos or unknown 11 (35.5) 40 (25.3) 
Active disease 14 (45.2) 80 (50.6) 
Unknown disease status 0 (0) 16 (10.1) 
CNS disease status before apheresis, n (%)   
CNS-1 0 (0) 96 (60.8) 
CNS-2 15 (48.4) 0 (0) 
CNS-3 16 (51.6) 0 (0) 
Unknown status 0 (0) 62 (39.2) 

MPAL, mixed-phenotype acute leukemia; neg, negative; pos, positive.

or Create an Account

Close Modal
Close Modal